Medical News / AHS ASM 2022 - CGRP Monoclonal Antibodies Show No Significant Impact on Persistent Headaches in Idiopathic Intracranial Hypertension

Secondary outcomes, assessed by the change in the number of monthly headache days by at least 25%, 75%, or 100%, were also not significant following treatment with CGRP monoclonal antibodies. Source: MDMag To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

At the 2022 ASPC annual meeting, Dr. Gluckman highlights the overall impact of the economic cost ... read more
The highest adjusted probability of CGM use occurred in middle adulthood, while the probability of CGM ... read more
Lasting 505 days, investigators documented the longest known COVID-19 infection. The research, presented at ECCMID, also ... read more
An ECCMID study found COVID-19 primary infections were more severe than reinfections, and vaccination further reduced ... read more